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The non-classical human leukocyte antigen-G (HLA-G), plays
an important role in inducing tolerance, through its immuno-
suppressive effects on all types of immune cells. Immune
tolerance is a key issue in the liver, both in liver homeostasis
and in the response to liver injury or cancer. It would
therefore appear likely that HLA-G plays an important role in
liver diseases. Indeed, this molecule was recently shown to
be produced by mast cells in the livers of patients infected
with hepatitis C virus (HCV). Furthermore, the number of
HLA-G-positive mast cells was signiﬁcantly associated with
ﬁbrosis progression. The generation of immune tolerance is a
role common to both HLA-G, as a molecule, and the liver, as
an organ. This review provides a summary of the evidence
implicating HLA-G in liver diseases. In the normal liver,
HLA-G transcripts can be detected, but there is no HLA-G
protein. However, HLA-G protein is detectable in the liver
tissues and/or plasma of patients suffering from hepatocellular
carcinoma, hepatitis B or C, or visceral leishmaniasis and in
liver transplant recipients. The cells responsible for producing
HLA-G differ between diseases. HLA-G expression is probably
induced by microenvironmental factors, such as cytokines.
The expression of HLA-G receptors, such as ILT2, ILT4, and
KIRD2L4, on liver cells has yet to be investigated, but these
receptors have been detected on all types of immune cells,
and such cells are present in liver. The tolerogenic propertiesJournal of Hepatology 20
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eﬁcial effects in transplantation. Given the key role of HLA-G
in immune tolerance, new therapeutic agents targeting
HLA-G could be tested for the treatment of these diseases in
the future.
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Human leukocyte antigen-G (HLA-G) is the best characterized
non-classical major histocompatibility complex (MHC) class
Ib molecule [1]. It is best known for its tolerogenic function
at the maternal-fetal interface, where it protects the fetus
from destruction by its mother’s immune system [2]. There
have been many studies of the role of HLA-G in tumors and
infectious diseases, autoimmunity and transplantation. We
suggest that HLA-G may play an important role in liver
diseases because: (i) it is tolerogenic; (ii) in the basal state,
its expression is restricted to tissues involved in immune
tolerance, such as the cornea and thymus [3,4]; and (iii) the
liver is an organ known to induce immunological tolerance
to T lymphocytes [5].
Mice have no HLA-G. Therefore, there is no murine model
of HLA-G deﬁciency, such as knockout (KO) mice, and Qa-2
is the putative functional homolog of HLA-G [6]. The only
HLA-G transgenic mice developed to date express H-2kb/
HLA-G [7]. However, this model differs from humans in that
HLA-G is expressed in all cells. The lack of an appropriate
murine model clearly hinders investigations of the function
of HLA-G in pathophysiology, including its role in liver
diseases.
This review aims to summarize the role of HLA-G in
cancers and infections of the liver in humans, and in liver
transplant recipients, together with a brief overview of the
characteristics of transplantation, after a brief review of
HLA-G and recent ﬁndings concerning its physiological expres-
sion in the liver.15 vol. 62 j 1430–1437
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JOURNAL OF HEPATOLOGYKey Points
• HLA-G, a non-classical MHC (major histocompatibility 
complex) class Ib molecule, is known to have 
tolerogenic properties and a restricted pattern of 
expression in healthy tissues
• HLA-G proteins are detected in the tissues and plasma 
of patients with hepatocellular carcinoma or viral 
hepatitis, and after liver transplantation
• Microenvironmental factors may influence the 
production of HLA-G by various cells, including tumor 
cells, cells of the monocyte lineage, mast cells, and 
biliary epithelial cells, with the cellular source of this 
molecule depending on the context
• HLA-G receptors (ILT2, ILT4, KIR2DL4) are present on 
all immune cells but have yet to be studied in liver cells. 
However, HLA-G is known to be detrimental in cancers, 
but beneficial in transplantation. Its role in hepatitis 
remains to be determined
• HLA-G may induce local temporary immune 
suppression, counteracting autoimmune or infection-
linked inflammatory responses and downregulating 
immune responses, such as the anti-tumor responseE1        E2          E3          E4 E5    E6   E7  3’UTRpromoter
Nucleus
Fig. 1. The HLA-G gene, transcripts and proteins. The HLA-G gene consists of 8
exons and 7 introns. Exon 1(E1) encodes the signal peptide, exon 7(E7) is not
transcribed and exons 2, 3 (E2, E3) and 4 (E4) encode the a-1 domain, the a-2
domain, and the a-3 domain, respectively; exon 5 (E5) encodes the transmem-
brane domain and exons 6 (E6) and 7 (E7) encode the cytoplasmic domain, with
the ﬁnal exon, exon 8 corresponding to the 30 UTR region. The star (⁄) in E6 as the
symbols in intron 2 and 4 are corresponding to stop codon. The primary transcript
produced by transcription of the HLA-G gene undergoes alternative splicing,
which generates four isoforms with transmembrane and cytoplasmic domains —
HLA-G1, -G2, -G3, -G4 — and three different soluble isoforms —sHLA-G1 or
HLA-G5, HLA-G6, and HLA-G7.Basic properties of HLA-G
The HLA-G gene is located on the short arm of chromosome 6, in
the HLA region (6p21.2-21.3), between the HLA-A and HLA-F
genes [8]. Its structure is similar to that of other HLA class I genes,
consisting of seven introns and eight introns, encoding the heavy
chain of the molecule (Fig. 1). Exon 1 encodes the signal peptide,
whereas exons 2, 3, and 4 encode the extracellular domains, a1,
a2, and a3, of the heavy chain, respectively. Exons 5 and 6 encode
the transmembrane and cytoplasmic domains. Exon 7 is never
present in the mature mRNA, due to the presence of a stop codon
in exon 6, and exon 8 is also not translated [9]. The HLA-G gene
promoter has an enhancer A (enh A), S and X1 sequence slightly
different from that of other class I genes, and a few alternative
regulatory elements to regulate HLA-G gene transcription [10].
The 30-UTR of the HLA-G gene also contains several regulatory
elements, including AU-rich motifs and a poly-A signal, inﬂuenc-
ing mRNA stability, turnover, mobility and splicing patterns [9].
HLA-G displays only limited polymorphism, with 50 alleles
(IMGT HLA database, December 2013) and 16 proteins, far fewer
than for some of the more highly polymorphic HLA class I
molecules.
The alternative splicing of primary transcripts is a key
feature of HLA-G, because it is strictly controlled and may be
subject to cell type-dependent regulation. Indeed, the primary
transcript of HLA-G is spliced into seven alternative mRNAs
encoding membrane-bound (HLA-G1, -G2, -G3, -G4) and soluble
(HLA- G5, -G6, -G7) protein isoforms [11]. In addition, HLA-G1 is
released into the medium by proteolytic cleavage, as shed
HLA-G1 [12].
The HLA-G1 mRNA encodes the full-length HLA-G molecule;
the HLA-G2 mRNA lacks exon 3, the HLA-G3 mRNA lacks exons
3 and 4, and the HLA-G4 mRNA lacks exon 4. HLA-G1 to -G4Journal of Hepatology 2015encode membrane-bound molecules, due to the presence of the
transmembrane domain and cytoplasmic tail encoded by exons
5 and 6. The HLA-G5mRNA is similar to HLA-G1 but retains intron
4, whereas the HLA-G6 mRNA lacks exon 3 but retains intron 4,
and the HLA-G7 mRNA lacks exon 3 but retains intron 2.
HLA-G5 and -G6 encode soluble forms, due to the presence of
intron 4, which contains a premature stop codon, preventing
translation of the transmembrane domain and the cytoplasmic
tail [12]. HLA-G7 encodes a soluble form, due to the presence of
intron 2, which contains a premature stop codon [13].
HLA-G is a transmembrane protein with a molecular weight of
39 kDa. It is a heterodimer of a heavy chain associated with a
light chain (b2-microglobulin). The heavy chain consists of three
globular domains (the a1, a2, and a3 domains), a transmem-
brane region and a short cytoplasmic domain. Seven protein
isoforms are generated by alternative splicing of the primary
transcript. HLA-G molecules can also form dimers through the
establishment of disulﬁde bonds between the two single
cysteine residues at positions 42 (Cys42-Cys42 bonds) and 147vol. 62 j 1430–1437 1431
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(Cys42-Cys147 bonds) of the HLA-G heavy chain [14]. The result-
ing HLA-G dimers bind receptors with a higher afﬁnity and
slower dissociation rates than monomers [15]. Another charac-
teristic of the HLA-G protein distinguishing it from other class I
proteins is its short cytoplasmic tail, which contains no endocyto-
sis motifs [16].
Unlike ubiquitously expressed HLA class I antigens, HLA-G
displays a restricted pattern of expression in healthy individuals
in basal conditions. The HLA-G protein is found only in
trophoblast cells, the placenta, cornea, thymus, proximal nail
matrix, erythroblasts and mesenchymal stem cells [2–4,17–21].
By contrast, soluble HLA-G (sHLA-G) is detectable in the
serum/plasma of both men and women. It is produced principally
by monocytes [21] and, to a lesser degree, T lymphocytes, in
particular conditions [22,23].
Furthermore, HLA-G expression is induced in many diseases,
including cancers, multiple sclerosis, inﬂammatory diseases and
viral infections and in transplantation [24].
HLA-G expression is controlled principally at the transcrip-
tional level, by a unique gene promoter, and at the posttranscrip-
tional level by mechanisms involving alternative splicing, mRNA
stability, translation and protein transport to the cell surface.
Many factors potentially affecting the transcriptional and
posttranscriptional mechanisms of HLA-G regulation have been
described previously [25].Factors involved in HLA-G liver expression
HLA-G expression generally depends strongly on factors present
in the microenvironment, such as cytokines. Indeed, various
cytokines, including interferons, interleukin (IL)-10, GM-CSF,
IL-2, and TGF-b increase HLA-G expression in several in vitro
models [25–27]. Other local factors, such as hypoxia [28] and
Indoleamine 2,3-dioxygenase [29], inﬂuence HLA-G expression.
These microenvironmental factors probably also play a role in
the liver. Support for this hypothesis is provided by the contro-
versies on HLA class I antigen expression on hepatocytes in basal
conditions and the induction of HLA class I molecule expression
in most hepatic diseases and its correlation with the intensity
of intralobular inﬂammation [30,31].
The expression proﬁles of microenvironmental factors differ
between diseases, but they may go some way towards explaining
HLA-G expression patterns in liver cancers, hepatitis and
transplantation. Moreover, epigenetic mechanisms, such as DNA
methylation and histone deacetylation, have been implicated in
cancers and in some anti-tumor treatments, and are known to
regulate HLA-G expression. In viral infections, the viral proteins
interfere with the intracellular trafﬁcking of HLA-G [32], provid-
ing an additional mechanism for the modulation of HLA-G
expression.Tolerogenic properties
The tolerogenic properties of HLA-G are mediated by the direct
binding of both soluble and membrane-bound HLA-G to inhibi-
tory receptors.
The binding to HLA-G of the immunoglobulin-like transcript
(ILT) receptor 2 (CD85j; LILRB1) on natural killer (NK) cells and
T lymphocytes leads to an inhibition of T lymphocyte or NK cell
function due to changes in proliferation, cytotoxicity or the1432 Journal of Hepatology 2015induction of regulatory T or NK cells [33]. The expression of
ILT2 on NK cells accounts for the restoration of NK cell cytotoxi-
city to hepatocellular carcinoma (HCC) cells transfected with
HLA-G1 after the addition of a blocking ILT2 HLA-G receptor
[34]. This receptor is also present on B lymphocytes and may
account for the higher tolerance of liver allografts expressing
HLA-G, due to the inhibition of B-cell antibody secretion [35].
The interaction of the CD8 receptor present on NK cells and T8
lymphocytes with sHLA-G triggers apoptosis [36]. This property
is shared by other soluble HLA class I antigens but elevated
sHLA-G levels are observed in neoplastic diseases. This results
in an inhibition of the immune response, particularly for the
anti-tumor response to liver cancers.
The role of the killer cell immunoglobulin-like receptor (KIR)
2DL4/p49 (CD158d) or KIR2DL4 expressed on NK cells and on
some CD8 T lymphocytes is complex, because this receptor may
have activating or inhibitory function [37]. The immunoglobu-
lin-like transcript 4 receptor, ILT-4 (CD85d; LILRB2) is known to
be expressed by dendritic cells (DCs), macrophages and mono-
cytes [38], all of which are present in the liver. The ILT-4/
HLA-G interaction may inhibit the antigen-presenting function
of these cells, weakening adaptive immunity and allowing liver
tumors to escape host immunity. This interaction may also
inhibit DC maturation, resulting in anergic DCs that induce the
differentiation of regulatory T cells, thereby helping to prolong
allograft survival [39]. However, primary human neutrophils also
express the ILT4 inhibitory receptor and the interaction of this
receptor with HLA-G inhibits the phagocytic function of
neutrophils [40]. This modulation of neutrophil activity may be
beneﬁcial in patients with sepsis, preventing the neutrophil
dysfunctions observed during inﬂammatory disorders.
CD160 is a HLA-G receptor expressed on endothelial cells,
which are abundant in the liver. The soluble HLA-G1 (sHLA-G1)
isoform has been reported to inhibit ﬁbroblast growth factor-2
(FGF2)–induced capillary-like tubule formation and, thus, to
inhibit FGF2-induced angiogenesis in vivo [41].
No data are currently available concerning the expression of
HLA-G receptors in liver. However, all of the immune cells
expressing these receptors, as described above, are found in the
liver, originating in most cases from the margination and
extravasation of cells circulating in the blood during pathological
conditions (Fig. 2). It also seems likely that the endothelial cells
of the liver express CD160. However, the expression of these
receptors on Kupffer cells, hepatocytes and hepatic stellate cells
has yet to be studied.
HLA-G is not expressed in the liver in physiological conditions,
however sHLA-G can be found, provided by peripheral blood or
from transendothelial migration of circulating cells in the liver.
HLA-G is able to induce tolerogenic DCs or regulatory T (Treg)
cells which are implicated in the maintenance of liver homeosta-
sis. Thus, it participates indirectly in inducing tolerogenic proper-
ties on immune cells to avoid activation of immune cells and
inﬂammation.HLA-G in the normal liver
HLA-G gene transcription has been observed in both fetal and
adult livers, but transcript levels are higher in fetal tissues. The
HLA-G transcript detected corresponded to the full-length form
[42]. The mesenchymal stem cells (MSC) present in fetal livervol. 62 j 1430–1437
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Fig. 2. Cellular source and putative targets of HLA-G in the liver. HLA-G has
been reported to be expressed by hepatocytes and mast cells, but there remains
some debate concerning its possible expression by hepatocytes. In certain
conditions, HLA-G may also be detected in T lymphocytes and in cells of the
monocytic lineage, such as monocytes or dendritic cells. The putative target cells
of HLA-G are peripheral cells expressing HLA-G receptors (T and B lymphocytes,
NK cells, monocytes), T lymphocytes and cells of the monocytic lineage present in
inﬂammatory areas, endothelial cells and mast cells.
JOURNAL OF HEPATOLOGYcontains intracellular deposits of HLA-G [43]. Hepatocyte-like
cells (HLCs) generated from human amniotic epithelial cells
(hAECs) from the placenta continue to secrete HLA-G [44], but
in smaller amounts, and this secretion is maintained in HLCs
differentiating from hAECs engrafted into the mouse liver [45].
No HLA-G protein is detected in hepatocytes and bile duct cells
from the normal liver (www.proteinatlas.org).HLA-G and liver cancer
Both HLA-G mRNA and protein are detectable in human HCC cell
lines [46].
HLA-G expression was found in 50.2% (110/219) of the pri-
mary HCCs assessed in one study; staining was heterogeneous
in these HCCs, but undetectable in the adjacent normal liver
tissues [34]. HLA-G expression has also been detected in biliary
cancers [47]. The HepG2 hepatocarcinoma cell line was found
to contain HLA-G mRNA, but not protein (www.proteinatlas.
org). The transfection of HepG2 cells with HLA-G1 decreases NK
cytolysis, whereas a blockade of HLA-G or its receptor ILT2
reverses this effect [34]. HLA-G expression is strongly associated
with advanced disease stage and patient age. In another series,
cytoplasmic HLA-G overexpression (99/173 cases), as revealed
by immunohistochemistry, was associated with a high risk of
poor survival and recurrence in patients in the early stages of
HCC. A positive correlation has also been found between HLA-G
levels and the Treg/CD8 T lymphocyte ratio [48]. These ﬁndings
are consistent with those of Wang [49], who detected HLA-G by
Western blot of liver tissues, at 66.7% (24/36) of the HCC sites
studied, but not in benign cirrhotic lesions. Survival after surgery
was shorter for patients with HLA-G-positive tumors than for
patients with HLA-G-negative tumors.Journal of Hepatology 2015Blood sHLA-G concentration was shown to be signiﬁcantly
higher in HCC patients (n = 36) than in patients with liver cirrho-
sis (n = 25) and healthy subjects (n = 25) [49]. Lin et al. also
reported a signiﬁcantly higher plasma sHLA-G concentration in
HCC patients (n = 19) than in healthy subjects (n = 86), with no
correlation between sHLA-G concentration and the staining of
the tumor for HLA-G [34]. The 14 bp insertion/deletion (in/del)
polymorphism of the 30 UTR of HLA-G is known to regulate
HLA-G expression. This led to studies of this polymorphism in
HCC patients. HLA-G expression was found to be stronger in
HCC tissues with a 14 bp del/del genotype than in those with a
heterozygous or 14-bp ins/ins genotype [50].
To conclude, HLA-G expression in liver tumor or high level of
sHLA-G in HCC patients allows escape of tumoral cells from
immune response in inhibiting the properties of immune cells
i.e. T8 lymphocytes, NK cells, B cells, DCs. HLA-G expression is a
factor of bad prognosis similarly to other cancers.HLA-G and viral hepatitis
HLA-G expression has been reported in the hepatocytes and bil-
iary epithelial cells of the livers of patients with chronic hepatitis
B [51]. Similar ﬁndings have been obtained for chronic hepatitis C
[52]. In a previous work, we found a strong HLA-G staining of
numerous cells in ﬁbrosis septa and not in hepatocyte nodules
of parafﬁn-embedded HCV liver. The HLA-G-positive cell number
is signiﬁcantly correlated with ﬁbrosis area on tissue sections of
HCV-induced liver ﬁbrosis. HLA-G-positive cells were identiﬁed
as being mast cells and not cells of monocytic lineage and T
lymphocytes as previously reported in other models. Mast cells
promote ﬁbrosis in other organs such as heart, lung and kidney.
As in other sites, hepatic mast cells may promote the activation
of liver ﬁbrosis via the proliferation of hepatic stellate cells
[53]. Cytokines involved in liver ﬁbrosis such as TGF-b, IL-4,
IL-33 are chemoattracting or activating for mast cell [54]. We
hypothesise that HLA-G can serve as a ﬁbrosis marker in reﬂect-
ing the number of mast cells [55] and in addition HLA-G makes
ﬁbrosis worse in favoring Th-2 cytokines proﬁle.
Plasma sHLA-G levels were higher in patients with hepatitis B
than in healthy subjects, regardless of disease stage, and HLA-G
levels were found to differ between stages. Indeed signiﬁcant dif-
ferences were observed between; (i) acute hepatitis B (n = 90)
and chronic hepatitis B (n = 131); (ii) acute hepatitis B and
resolved hepatitis B (n = 152); and (iii) chronic hepatitis B and
resolved hepatitis B [56]. Similarly, chronic hepatitis C patients
(n = 67), were found to have a much higher plasma sHLA-G
concentration than healthy subjects (n = 129) [57].HLA-G and hepatotropic parasite infections
Visceral leishmaniasis (Leishmania infantum) (VL) causes mor-
phological and functional disturbances in the liver, resulting in
focal ﬁbrosis rather than cirrhosis. We showed that sHLA-G levels
were higher in 35% of HIV-negative patients with VL and in 57%
of patients coinfected with HIV and Leishmania infantum than in
healthy individuals [58]. This upregulation of sHLA-G was
reported to be correlated with cyst activity [59]. HLA-G
expression could constitute an immune-evasion strategy in the
host-parasite interplay.vol. 62 j 1430–1437 1433
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HLA-G and liver failure
HLA-G expression during liver failure has not yet been investi-
gated, to the best of our knowledge. Data are available only for
septic shock. There is a critical reduction of tissue perfusion
during severe sepsis and septic shock that may trigger the acute
failure of multiple organs, including the liver. A sustained,
marked increase in plasma sHLA-G levels was found to be predic-
tor of survival [60]. A tissue expression of HLA-G or an increase of
plasma levels would reﬂect an appropriate and efﬁcient response
to the inﬂammatory process in limiting this process.HLA-G and autoimmune hepatic diseases
The role of HLA-G has been investigated in several inﬂammatory
diseases, including multiple sclerosis, rheumatoid arthritis,
systemic lupus erythematous, and psoriasis, and it has been
suggested that HLA-G is both a biomarker useful for the
monitoring of disease activity and an anti-inﬂammatory
molecule [24]. However, no data have yet been published for
autoimmune hepatic diseases, such as autoimmune hepatitis,
sclerosing cholangitis and primary biliary cirrhosis. Similarly to
other inﬂammatory diseases, HLA-G molecules may play a
protective role in autoimmune hepatic diseases by its anti-
inﬂammatory activity.HLA-G and liver transplantation
In combined liver-kidney transplantation, immunohistochem-
istry revealed HLA-G expression in 14 of the 40 liver biopsy speci-
mens and ﬁve of the nine kidney transplant biopsy specimens
examined. HLA-G is expressed de novo by known target cells of
acute rejection: liver epithelial cells, but not in hepatocytes and
renal tubular epithelial cells. HLA-G expression in the liver allo-
graft is associated with a lower frequency of hepatic and renal
graft rejection [61]. An inverse correlation was also found
between serum HLA-G concentration and liver function in liver
transplant patients (n = 37). Indeed, a decrease in serum HLA-G
concentration was found to be predictive of liver dysfunction or
rejection one month later.
Serum sHLA-G concentration was high in liver-kidney trans-
plant patients but not in kidney transplant patients [61]. Thus,
sHLA-G levels and cell surface HLA-G expression on regulatory
T cells increase during cyclosporine treatment and can be used
in the follow-up of liver transplant patients [39]. Similarly,
increases in serum HLA-G levels in pediatric and young adult
liver transplant patients can be used to detect tolerance of the
liver graft and to predict favorable outcomes in liver transplant
recipients [62]. Serum sHLA-G concentration appears to be higher
in adult liver transplant recipients treated with tacrolimus as an
immunosuppressive agent, but this difference is not statistically
signiﬁcant [63]. Higher levels of expression have also been
reported on the circulating monocytoid DCs (mDCs) of patients
with operational liver transplant tolerance than in patients on
maintenance immunosuppression or healthy controls, although
these differences were, again, not statistically signiﬁcant [64].
The immunosuppressive treatments used in liver transplantation
can modulate HLA-G expression, and this may partly account for
their impact on prognosis. Indeed, some therapeutic agents such1434 Journal of Hepatology 2015as dexamethasone and hydrocortisone, upregulate HLA-G expres-
sion [65]. Cyclosporine and tacrolimus are the principal
immunosuppressive agents used in liver transplantation, and
mycophenolate is used to treat renal failure. Cyclosporine A and
mycophenolate have no effect on HLA-G expression [66], whereas
tacrolimus increases sHLA-G levels [63].
To conclude this section, expression of HLA-G in liver tissue or
increase of circulating sHLA-G is associated with a better graft
acceptance, that hypothesis is reinforced by the upregulation of
HLA-G by some therapeutic agents used to prevent rejection.HLA-G and graft vs. host response
Liver is one of the sites at which graft vs. host (GVH) disease
following hematopoietic stem cell transplantation is observed.
Examination of the liver during acute GVH reveals foci of
eosinophilic necrosis, bile duct destruction, Kupffer cell
hypertrophy and peribiliary lymphocytic inﬁltrates. Fibrosis and
atrophy are observed in chronic cases of GVH disease.
It seems likely that sHLA-G is involved in acute GVH disease
(aGVHD) prevention, because increases in sHLA-G5 concentration
on post-transplant days 15 and 30 were found to be inversely
correlated with aGVHD severity [67]. This role of sHLA-G5 may
be accounted for by the positive correlation between sHLA-G
level and natural Treg cell frequency in the blood of transplant
patients [68].General discussion
The cellular source of HLA-G differs between diseases. HLA-G is
produced by some tumor cells, but it may also be generated by
cells of the monocytic lineage, including monocytes, and DCs or
T lymphocytes may express HLA-G in particular conditions.
Furthermore, we have demonstrated the involvement of another
cell type in HCV-induced liver ﬁbrosis. Indeed, in this condition, it
is the mast cells that produce HLA-G [55]. In the context of trans-
plantation, HLA-G may be secreted by the biliary epithelial cells
of the liver graft [61]. Alternatively, HLA-G5 may be secreted by
allo-speciﬁc CD4+ T lymphocytes, as shown in mixed lymphocyte
cultures in vitro [22]. Kupffer cells or DCs may also serve as a
source of HLA-G during transplantation, because both monocytes
and DCs can express or secrete sHLA-G [21,69].
Numerous studies in the ﬁeld of transplantation have demon-
strated an association between high levels of HLA-G expression in
biopsy specimens or high blood sHLA-G levels and higher rates of
graft acceptance. Indeed, this association with a better post-
transplantation outcome was ﬁrst demonstrated for heart trans-
plantation [70,71], and then for the transplantation of liver
[39,61,72], kidney [73,74] and lung [75] grafts and for the trans-
plantation of hematopoietic stem cells [68]. This beneﬁcial effect
may reﬂect a peripheral increase in the size of the CD3+CD4low
and CD3+CD8low T-cell subpopulations associated with high
levels of peripheral IL-10 production [76]. These two subsets con-
stitute novel blood suppressor T-cell populations and are induced
by HLA-G, potentially accounting for transplant tolerance.
Patients with high sHLA-G levels after transplantation overpro-
duce these suppressor T cells. HLA-G induces several types of
regulatory/suppressive cells of various subtypes. The orientation
towards tolerance can be accounted for by the effects of HLA-Gvol. 62 j 1430–1437
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on the different subtypes of immune cells, including B cells in
particular, resulting in the inhibition of antibody secretion by B
cells in a mouse xenograft model [35]. Graft acceptance has been
shown to be better in patients undergoing liver transplantation or
combined liver-kidney transplantation than in those undergoing
kidney transplantation alone [61]. These data are consistent
with the immunological status of the liver [5]. The better graft
tolerance observed in patients overexpressing HLA-G may be
attributed to liver factors. These liver factors may be cytokines,
such as the IL-10 produced by the liver during liver trans-
plantation [77,78], HLA-G secreted by the biliary epithelial cells
of the grafted liver [72] or allo-speciﬁc CD4+ T lymphocytes, as
shown in mixed lymphocyte culture in vitro [22]. Two other
possible sources of HLA-G during transplantation are the
Kupffer cells and hepatic DCs, which belong to the monocytic
lineage able to produce or secrete HLA-G. Alternatively, HLA-G
expression, which may be restricted to a few cells, could be
propagated to neighboring cells by trogocytosis [79].
The tolerogenic properties of HLA-G account for its deleteri-
ous effects in cancers and beneﬁcial effects in transplantation.
The abnormal expression of HLA-G in HCC cell lines plays an
important role in protecting these cells against NK cell attack.
The signiﬁcant correlation between HLA-G expression and NK cell
lysis implies that abnormal HLA-G expression may contribute to
the mechanism of escape from host immune surveillance in
HCC. Indeed, the effects of HLA-G on immune cells greatly affect
both innate and adaptive immune responses, allowing the HCC to
escape host immunity, resulting in tumor progression. Moreover,
a comparison of HLA-G with the carcinoembryonic antigen AFP as
markers of cancer has shown that HLA-G is speciﬁc to malignant
liver cancers, like AFP in breast and ovarian cancers [80]. A posi-
tive correlation between HLA-G and Treg/CD8 T-cell ratio, with a
negative impact of HLA-G on outcome, can be accounted for by
the immunosuppressive properties of HLA-G and Treg cells.
Other studies have demonstrated an association between
HLA-G and Treg, due to the induction, by HLA-G, of different
populations of Treg cells. Thus HLA-G appears to be an indepen-
dent indicator of poor outcome in HCC, particularly during the
early stages of the disease [48].
Plasma HLA-G concentration may be useful for the monitoring
of immunosuppressive therapy after transplantation. The func-
tion of HLA-G in viral infections remains to be determined and
may be detrimental, as in cancers, or beneﬁcial, as in septic shock.
The receptors of HLA-G have not yet been investigated in the
liver, and such studies are required if we are to understand the
function of HLA-G.Conclusions
HLA-G could generally be considered a potent tolerogenic
molecule. Its immunosuppressive properties play a role in liver
diseases and transplantation, with negative effects on cancers
and beneﬁcial effects in liver transplantation. HLA-G may
constitute a novel therapeutic target in the future. Indeed, new
therapeutic agents for modulating HLA-G expression are being
developed and tested, including synthetic HLA-G proteins poten-
tially useful in transplantation [81] and antibodies blocking
HLA-G activity in cancer [82]. Further exploration of the role of
HLA-G receptors in liver diseases and a better knowledge of
its function in liver are also required before considering their
potential use in liver diseases.Journal of Hepatology 2015Conﬂict of interest
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